Status:
APPROVED_FOR_MARKETING
Long Term Treatment With L-DOPS
Lead Sponsor:
Vanderbilt University
Conditions:
Dopamine Beta Hydroxylase (DBH) Deficiency
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect...
Eligibility Criteria
Inclusion
- 18 years old or older with orthostatic hypotension
- established diagnosis of DBH deficiency and fractionated plasma catecholamine levels that show high dopamine levels and very low norepinephrine and epinephrine levels. Blood pressure increase in response to oral treatment with L-DOPS during previous studies.
Exclusion
- subjects with orthostatic hypotension that do not have a genetic form of the disorder and catecholamine pattern is not consistent with that above.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
EXPANDED_ACCESS
End Date :
June 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00889135
Start Date
September 1 2004
End Date
June 1 2015
Last Update
October 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232